Payment overview · 2025
General Payments
$214,375.61
383 reported records · 27 companies
Healthcare provider profile · identity verified
John Charles Isaac, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · HOUSTON, TX · NPI 1295799005
Verified facts
What the public records show
CMS Open Payments records show John Charles Isaac, M.D. received $214,375.61 in general payments during 2025 across 383 reported records.
Amgen Inc. accounted for 59.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Farxiga, Jardiance, Nexletol, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 881 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 881 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $127,761.91 | 59.6% | 185 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $21,212.24 | 9.9% | 38 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20,135.11 | 9.4% | 27 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $19,529.66 | 9.1% | 23 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13,964.69 | 6.5% | 14 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $5,000.00 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,569.29 | 1.2% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,964.35 | 0.9% | 13 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $312.30 | 0.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $304.11 | 0.1% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $240.42 | 0.1% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $237.13 | 0.1% | 11 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $224.41 | 0.1% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $152.20 | 0.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.76 | 0.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $118.62 | 0.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $111.29 | 0.1% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$103.00 | 0.1% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $58.61 | 0.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.14 | 0.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.58 | 0.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.81 | 0.0% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $30.48 | 0.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.83 | 0.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.95 | 0.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $19.50 | 0.0% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $19.22 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $171,043.39 | 77 |
| Travel and Lodging | $19,030.93 | 127 |
| Consulting Fee | $15,907.50 | 3 |
| Food and Beverage | $8,373.57 | 175 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $127,690.43 | 184 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $21,212.24 | 38 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19,960.36 | 23 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $19,529.66 | 23 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $11,533.98 | 16 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $5,000.00 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $1,964.35 | 13 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $312.30 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $296.20 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $234.52 | 13 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $176.88 | 7 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $152.20 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.76 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $135.70 | 7 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $118.62 | 5 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $103.00 | 1 | 2025 |
Source payment records
|
|||||
| CONFIRM RX Normalized: confirm rx |
Device | Abbott Laboratories | $86.61 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.06 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.54 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $47.95 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.14 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.14 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 881 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 154 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
175 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
154 | 47 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 48 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
881 | 228 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
181 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 48 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
256 | 71 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
881 | 228 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 2335 | 744 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1749 | 552 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1643 | 486 |
| Repatha Sureclick | Evolocumab | 1403 | 217 |
| Metoprolol Succinate | Metoprolol Succinate | 1146 | 329 |
| Amlodipine Besylate | Amlodipine Besylate | 950 | 296 |
| Eliquis | Apixaban | 881 | 228 |
| Clopidogrel | Clopidogrel Bisulfate | 645 | 190 |
| Valsartan | Valsartan | 406 | 130 |
| Furosemide | Furosemide | 349 | 135 |
| Nebivolol Hcl | Nebivolol Hcl | 323 | 93 |
| Losartan Potassium | Losartan Potassium | 313 | 99 |
| Lisinopril | Lisinopril | 310 | 101 |
| Praluent Pen | Alirocumab | 302 | 57 |
| Carvedilol | Carvedilol | 290 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 81 |
| Entresto | Sacubitril/Valsartan | 256 | 71 |
| Vascepa | Icosapent Ethyl | 255 | 75 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 214 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 61 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 181 | 51 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 178 | 56 |
| Xarelto | Rivaroxaban | 177 | 52 |
| Brilinta | Ticagrelor | 175 | 40 |
| Icosapent Ethyl | Icosapent Ethyl | 167 | 58 |
| Jardiance | Empagliflozin | 165 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 155 | 46 |
| Farxiga | Dapagliflozin Propanediol | 154 | 47 |
| Potassium Chloride | Potassium Chloride | 151 | 51 |
| Multaq | Dronedarone Hcl | 138 | 40 |
| Spironolactone | Spironolactone | 137 | 43 |
| Irbesartan | Irbesartan | 100 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 30 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 85 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 83 | 38 |
| Ozempic | Semaglutide | 72 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 19 |
| Nitroglycerin | Nitroglycerin | 69 | 36 |
| Simvastatin | Simvastatin | 65 | 18 |
| Atenolol | Atenolol | 64 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 22 |
| Ramipril | Ramipril | 63 | 17 |
| Labetalol Hcl | Labetalol Hcl | 62 | 18 |
| Nifedipine Er | Nifedipine | 62 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 13 |
| Enalapril Maleate | Enalapril Maleate | 51 | 13 |
| Ranolazine Er | Ranolazine | 51 | 15 |
| Sotalol | Sotalol Hcl | 51 | 18 |
| Digoxin | Digoxin | 47 | 17 |
| Minocycline Hcl | Minocycline Hcl | 47 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 15 |
| Benazepril Hcl | Benazepril Hcl | 39 | 12 |
| Clonidine Hcl | Clonidine Hcl | 38 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | 12 |
| Torsemide | Torsemide | 37 | 12 |
| Corlanor | Ivabradine Hcl | 36 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 11 |
| Telmisartan | Telmisartan | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 21 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Sotalol Af | Sotalol Hcl | 17 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $214,375.61 · 383 records | Amgen Inc. | AMVUTTRA, AREXVY, Assure WCD, CAMZYOS, CAPVAXIVE, CARDIOMEMS, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, COBALT DR MRI SURESCAN, CONFIRM RX, EDARBI, ELIQUIS, EVKEEZA, FARXIGA, FFRct, FREESTYLE LIBRE 3, FUROSCIX, General - Therapies, INSPIRE, JARDIANCE, JOT DX, Kerendia, LEQVIO, LifeVest, NEXLETOL, NURTEC ODT, OPSUMIT, Optimizer, Ozempic, PAXLOVID, REPATHA, Rybelsus, SHINGRIX, VERQUVO, WAINUA, Wegovy, Zypitamag | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error